Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Significant Growth in Short Interest

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 1,536,000 shares, a growth of 243.1% from the January 15th total of 447,700 shares. Based on an average daily volume of 2,008,300 shares, the days-to-cover ratio is currently 0.8 days.

Bayer Aktiengesellschaft Trading Up 0.9 %

Bayer Aktiengesellschaft stock traded up $0.05 during midday trading on Thursday, hitting $5.52. 648,213 shares of the stock were exchanged, compared to its average volume of 1,011,742. The company has a quick ratio of 0.81, a current ratio of 1.32 and a debt-to-equity ratio of 1.19. The stock has a market capitalization of $21.69 billion, a PE ratio of -21.23 and a beta of 1.04. The company has a fifty day simple moving average of $5.24 and a two-hundred day simple moving average of $6.43. Bayer Aktiengesellschaft has a 52 week low of $4.79 and a 52 week high of $8.58.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Tuesday, November 12th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.10). The firm had revenue of $10.96 billion for the quarter. Bayer Aktiengesellschaft had a positive return on equity of 16.90% and a negative net margin of 2.02%. Equities research analysts anticipate that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.